BMY Q1 2021 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q1 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.1B+2.7% YoY

Gross Profit

$6.1B55.0% margin

Operating Income

$2.2B19.8% margin

Net Income

$2.0B18.3% margin

EPS (Diluted)

$0.89

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

$3.8B

Free Cash Flow

$3.7B

Stock-Based Comp.

$151M

Balance Sheet

Total Assets

$112.4B

Total Liabilities

$74.8B

Stockholders' Equity

$37.6B

Cash & Equivalents

$11.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.1B	$10.8B	+2.7%
Gross Profit	$6.1B	$4.8B	+25.5%
Operating Income	$2.2B	$928M	+136.7%
Net Income	$2.0B	-$775M	+360.8%

Revenue Segments

Revlimid

$2.9B27%

Eliquis

$2.9B26%

Opdivo

$1.7B16%

Pomalyst/Imnovid

$773M7%

Orencia

$758M7%

Sprycel

$470M4%

Yervoy

$456M4%

Mature Products And All Other

$339M3%

Abraxane

$314M3%

Baraclude

$113M1%

Reblozyl

$112M1%

Empliciti

$85M1%

Zeposia

$18M0%

Geographic Segments

UNITED STATES

$7.0B63%

Europe

$2.6B23%

Rest Of World

$1.3B12%

Other Region

$164M1%